Ipca Laboratories’ Tarapur API Facility Gets VAI Classification From US FDA

    Synopsis:


    Ipca Laboratories’ Active Pharmaceutical Ingredients (API) facility at Tarapur (Palghar, Maharashtra) has been classified as Voluntary Action Indicated (VAI) by the US FDA, indicating a minimally acceptable state of CGMP compliance. This follows inspection during 1–5 Dec 2025.


    Source:
    IPCA Laboratories Press Release (NSE Exchange Fillings) | Published on Feb 07, 2025

    Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.

    As quoted in the press release of IPCA Laboratories (NSE Exchange Filings), the company has received the Establishment Inspection Report for its Active Pharmaceutical Ingredients manufacturing facility located at Tarapur in Palghar district, Maharashtra. The inspection was carried out by the United States Food and Drug Administration between 1 December and 5 December 2025.

    The inspection outcome classifies the Tarapur facility as Voluntary Action Indicated. This classification signifies that the facility is considered to be in a minimally acceptable state of compliance with current good manufacturing practices. The update was disclosed under the company’s regulatory obligations as per applicable listing regulations.

    Also Read: Reliance Consumer Acquires Majority Stake In Australia’s Goodness Group

    Ipca Laboratories Ltd

    Trade

    1762.7-8.50 (-0.47 %)

    Updated - 24 July 2026
    1788.90day high
    DAY HIGH
    1747.00day low
    DAY LOW
    79195
    VOLUME (BSE)

    Key Takeaways

    • The US FDA inspected Ipca Laboratories’ Tarapur API facility from 1 to 5 December 2025

    • The Establishment Inspection Report classifies the facility as Voluntary Action Indicated

    • VAI status confirms minimal compliance with current good manufacturing practices

    • The classification does not involve regulatory enforcement action

    • The update relates specifically to the Tarapur API manufacturing unit

    What the VAI Classification Indicates

    A Voluntary Action Indicated classification is issued when certain observations are noted during an inspection, but these observations do not meet the threshold for regulatory action. Facilities with this status are considered operationally acceptable, provided that identified issues are addressed through routine corrective processes.

    For pharmaceutical manufacturers, the outcome indicates that production can continue without interruption, subject to internal compliance measures. The classification also suggests that the facility meets baseline regulatory requirements, even though improvements may be expected as part of standard quality management systems.

    Ipca Laboratories operates multiple manufacturing facilities across India and supplies pharmaceutical products to both domestic and international markets. Regulatory inspections form a routine part of oversight for companies with exposure to regulated markets such as the United States.

    Regulatory Compliance Context

    The Tarapur facility plays a role in Ipca Laboratories’ API manufacturing operations. Inspections by overseas regulators are a standard requirement for facilities supplying regulated markets. The December 2025 inspection and subsequent Establishment Inspection Report form part of this ongoing regulatory process.

    The company had earlier informed stock exchanges about the inspection under disclosure requirements. The receipt of the inspection report completes the regulatory update cycle related to this specific inspection event.

    Aspect

    Detail

    Company

    Ipca Laboratories Limited

    Facility

    API Manufacturing Unit, Tarapur

    Location

    Palghar, Maharashtra

    Inspection Period

    1–5 December 2025

    Regulatory Authority

    US FDA

    Inspection Outcome

    Voluntary Action Indicated

    Compliance Status

    Minimally acceptable CGMP compliance

    Share Price Update

    Ipca Laboratories share price stands at ₹1,416.70 per share on the BSE as of 6 February 2026 at 15:30 IST, down by 1.76%. The IPCA share price movement reflects routine market activity on the day following the regulatory update.

    Also Read: Power Finance Corporation Acquires Majority Stake in REC Ltd

    Published Date : 09 Feb 2026

    Disclaimer :

    Investments in securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

    The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

    The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and/or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

    Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

    BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.


    Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited



    This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing. 

    For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

    Read More Blogs

    Our Secure Trading Platforms

    Level up your stock market experience: Scan the QR to download the Bajaj Broking App for effortless investing and trading

    QR code to download Bajaj Broking App

    9 lakh+ Users

    icon-with-text

    4.9 App Rating

    icon-with-text

    4 Languages

    icon-with-text

    ₹7,000 Cr+ MTF Book

    icon-with-text